Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyCBHA Respiratory Panel Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCarolina Behavioral Health Alliance (CBHA)Policy CP.MP.181

    Polymerase Chain Reaction Respiratory Viral Panel Testing

    Customize your policy alerts

    Sign up for carolinabehavioralhealth Policy CP.MP.181 alerts

    Get alerted when Policy CP.MP.181 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and coding support for multiplex respiratory viral panel testing for non-Medicare plans affiliated with Centene Corporation, including panels testing five or fewer pathogens and panels testing six or more pathogens.

    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyPolymerase Chain Reaction Respiratory Viral Panel Testing
    Policy CodePolicy CP.MP.181
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the clinical indication, reasons for panel testing, provider specialty, and place of service in the medical record.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The policy added separate medical-necessity criteria for panels testing five or fewer pathogens and panels testing six or more pathogens.

    The policy added outpatient indications for testing other pathogens when COVID-19 is suspected but COVID-19 testing is not available soon enough to influence the plan of care, when the patient is immunocompromised, or when testing is ordered by an infectious-disease specialist or when such a specialist is unavailable.

    The policy moved CPT codes 87632 and 87633 to a medically necessary code table when billed with applicable place-of-service codes.

    The policy added procedure codes 0098U, 0099U, 0100U, and 0115U to the medically necessary code listings.

    The policy added a note directing readers to CP.MP.183 for 2019-novel coronavirus testing.

    ≤5Panel size with standard criteria
    ≥6Panel size requiring additional criteria
    87631CPT code for 3–5 targets
    87632–87633CPT codes for 6–25 targets
    4Listed hospital-based settings

    Medical Necessity Criteria

    Panels Testing Five Pathogens or Fewer

    Covered when ALL of the following criteria are met:

    ALL of the following

    • ONE of the following clinical indications

      • The member/enrollee is immunocompetent, and the clinical indication includes a presumption of active infection or infection-associated complications, which may include exacerbation of underlying disease, that require identification of a causative organism for appropriate management.

        Atypical clinical presentations are appropriate indications for special populations who may not present with classic symptoms of infection, such as elderly individuals.

      • The member/enrollee is immunocompromised, including individuals with HIV or AIDS; those taking immunosuppressive medications such as chemotherapy, biologics, transplant-related immunosuppressive drugs, or high-dose systemic corticosteroids; and those with inherited diseases affecting the immune system, such as congenital immunoglobulin deficiencies.

        Atypical clinical presentations are appropriate indications for testing. In this population, testing may be performed once as part of a pre-transplant evaluation, regardless of the presence of symptoms.

    • The results of testing will impact clinical management in a manner already demonstrated in peer-reviewed published literature to improve outcomes.
    • Testing is performed according to the intended use of the test in the intended population for which the test was developed and validated.
    • Targeted testing is not appropriate because it will not provide sufficient information for appropriate clinical management.
    • The panel includes at least the minimum pathogens required for clinical decision making for its intended use that can be reasonably detected by the test.
    • The registered test demonstrates equivalent or superior analytical validity and clinical validity to established standard-of-care methods, such as culture or pathogen-specific PCR, for the majority of targets included on the panel.
    • Documentation in the medical record

      • Specific clinical indications for testing, such as clinical suspicion of a pathogen as the cause of the medical condition, are clearly stated.
      • Specific reasons for performing panel testing are clearly stated.
      • The provider type or specialty and Place of Service are clearly stated.

    Panels Testing Six Pathogens or More

    Covered when the criteria in the five-pathogen-or-fewer section are met, plus at least ONE of the following criteria:

    ONE of the following

    • Testing is performed in a healthcare setting that cares for critically ill individuals, such as the emergency department or inpatient hospital, including individuals in observation status.
    • The member/enrollee is immunocompromised, as defined in the immunocompromised-indication criterion in Section I.A.2.
    • Both of the following

      • The member/enrollee is immunocompetent and has a severe and established underlying respiratory pathology, such as severe asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, or radiation therapy to the lung.
      • Treatment with antibiotics may be indicated according to established guidelines.

    Qualifying Clinical Indications

    Covered Indications

    Covered indications include the following; for panels testing six or more pathogens, the section I criteria must also be met:

    Qualifying covered indication

    • Suspected active infection or infection-associated complication: The member is immunocompetent and has a suspected active respiratory infection or infection-associated complication, which may include exacerbation of underlying disease, requiring identification of a causative organism for appropriate management. Atypical presentations may qualify in special populations, such as elderly members.
    • Immunocompromised member: The member is immunocompromised. Atypical presentations may qualify; one test may be performed as part of a pre-transplant evaluation regardless of symptoms.
    • Critical-care evaluation for a larger panel: For a panel testing six or more pathogens, testing is performed in a healthcare setting that cares for critically ill individuals, such as an emergency department or inpatient hospital, including observation status.

    Testing Frequency

    Frequency limit
    TestRespiratory viral panel (RVP) testing
    PopulationImmunocompromised member
    FrequencyOnce as part of a pre-transplant evaluation, regardless of the presence of symptoms

    Covered Codes and Billing Categories

    CPT codes that support medical necessity in any place of service, without diagnosis code requirementsCPTCovered
    87631Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, including multiplex reverse transcription when performed and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
    CPT and PLA codes that support medical necessity when billed with listed place-of-service or diagnosis-code combinationsmixedCovered
    0115URespiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
    0202UInfectious disease, bacterial or viral respiratory tract infection, pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
    0223UInfectious disease, bacterial or viral respiratory tract infection, pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
    0225UInfectious disease, bacterial and viral respiratory tract infection, pathogen-specific DNA and RNA, 21 targets including SARS-CoV-2, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
    87632Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, including multiplex reverse transcription when performed and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
    87633Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, including multiplex reverse transcription when performed and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
    Place of service codes supporting medical necessity for codes in Table 2Revenue
    19Off Campus- Outpatient Hospital.
    21Inpatient Hospital.
    22Outpatient Hospital (Observation).
    23Emergency Room Hospital.
    ICD-10-CM diagnosis codes supporting medical necessity for Table 2 codesICD-10Covered
    A37.00Whooping cough due to Bordetella pertussis without pneumonia.
    A37.01Whooping cough due to Bordetella pertussis with pneumonia.
    A37.10Whooping cough due to Bordetella parapertussis without pneumonia.
    A37.11Whooping cough due to Bordetella parapertussis with pneumonia.
    A37.80Whooping cough due to other Bordetella species without pneumonia.
    A37.81Whooping cough due to other Bordetella species with pneumonia.
    A37.90Whooping cough, unspecified species without pneumonia.
    A37.91Whooping cough, unspecified species with pneumonia.
    A41.81Sepsis due to Enterococcus.
    A41.89Other specified sepsis.
    1–10 of 71
    1/8
    Respiratory viral panel procedure codes referenced in revision historyCPTCovered
    87632Respiratory viral panel procedure code; exact description not visible in this window
    87633Respiratory viral panel procedure code; exact description not visible in this window
    0098UMedically necessary respiratory viral panel procedure code; exact description not visible in this window
    0099UMedically necessary respiratory viral panel procedure code; exact description not visible in this window
    0100UMedically necessary respiratory viral panel procedure code; exact description not visible in this window
    0115UMedically necessary respiratory viral panel procedure code; exact description not visible in this window
    Respiratory and infectious diagnosis codes supporting medical necessityICD-10Covered
    J15.3Pneumonia due to other streptococci, group B
    J15.4Pneumonia due to other streptococci
    J15.61Pneumonia due to Acinetobacter baumannii
    J15.69Pneumonia due to other Gram-negative bacteria
    J15.7Pneumonia due to Mycoplasma pneumoniae
    J15.8Pneumonia due to other specified bacteria
    J15.9Unspecified bacterial pneumonia
    J16.0Chlamydial pneumonia
    J16.8Pneumonia due to other specified infectious organisms
    J18.0Bronchopneumonia, unspecified organism
    1–10 of 59
    1/6
    Diagnosis codes supporting medical necessity for respiratory viral panel CPT codesICD-10Covered
    B20Human immunodeficiency virus [HIV] disease
    C46.0Kaposi's sarcoma of skin
    C46.1Kaposi's sarcoma of soft tissue
    C46.2Kaposi's sarcoma of palate
    C46.3Kaposi's sarcoma of lymph nodes
    C46.4Kaposi's sarcoma of gastrointestinal sites
    C46.50Kaposi's sarcoma of unspecified lung
    C46.51Kaposi's sarcoma of right lung
    C46.52Kaposi's sarcoma of left lung
    C46.7Kaposi's sarcoma of other sites
    1–10 of 124
    1/13
    CPT/HCPCS codes mentioned in revision historyCPT
    87632Moved to a table of medically necessary codes when billed with place-of-service codes in Table 3.
    87633Moved to a table of medically necessary codes when billed with place-of-service codes in Table 3.
    0098UAdded as medically necessary when billed with place-of-service codes in Table 3; later deleted from the CPT table.
    0099UAdded as medically necessary when billed with place-of-service codes in Table 3; later deleted from the CPT table.
    0100UAdded as medically necessary when billed with place-of-service codes in Table 3; later deleted from the CPT table.
    0115UAdded as medically necessary when billed with place-of-service codes in Table 3.
    Additional CPT codes mentioned in revision historyCPT
    0202UAdded to CPT table 2.
    0223UAdded to CPT table 2.
    0225UAdded to CPT table 2.
    ICD-10 codes added to Table 4ICD-10
    J15.61Added to ICD-10 Table 4.
    J15.69Added to ICD-10 Table 4.
    ICD-10 codes added to Table 5ICD-10
    J44.81Added to ICD-10 Table 5.
    J44.89Added to ICD-10 Table 5.
    Place of Service code mentioned in revision historyRevenue
    19Place of Service Code 19 added to Table 3.
    Small respiratory viral panel
    Panel categorySmall respiratory viral panel
    Pathogen limit5 pathogens or fewer
    Coverage standardMedically necessary when all applicable criteria are met
    Large respiratory viral panel
    Panel category

    Documentation and Denial Risk

    Documentation Required

    Required Medical-Record Documentation

    The medical record must clearly document the specific clinical indication for testing, including the clinical suspicion of a pathogen as the cause of the medical condition. Also document the specific reasons for performing panel testing, the provider type or specialty, and the Place of Service.

    Denial Risk

    Medical-Necessity Denial Risk

    Respiratory viral panel testing may be denied when the medical-necessity criteria are not met. The record must support a qualifying infectious-disease indication, demonstrate that results will affect clinical management in a manner shown to improve outcomes, and establish that the testing is performed according to its validated intended use.

    • No qualifying clinical indication or no presumption of active infection or infection-associated complication requiring identification of a causative organism.
    • Testing results are not expected to have a demonstrated clinical impact on management.

    Respiratory Viral Panel Testing

    Respiratory viral polymerase chain reaction (PCR) panels are multiplex tests that detect RNA or DNA from multiple respiratory viruses in a single assay. Specimens are commonly collected using nasal, nasopharyngeal, or oropharyngeal swabs. Depending on the test, panels may identify pathogens such as rhinovirus, parainfluenza virus, coronavirus, adenovirus, respiratory syncytial virus, human metapneumovirus, and influenza virus. PCR testing can support timely identification of infection, appropriate antiviral use, infection-control decisions, and reduction of unnecessary antibiotic treatment; however, identifying a specific pathogen does not always change management for an individual patient.

    Key Terms

    Respiratory viral panel (RVP)
    DefinitionA single test that may detect RNA or DNA from multiple types of respiratory viruses
    Common specimenNasal swab
    Other specimensNasopharyngeal or oropharyngeal swab
    Immunocompromised
    DefinitionAn individual with a weakened immune system
    Acquired causesHIV or AIDS; immunosuppressive medications such as chemotherapy, biologics, transplant-related immunosuppressive drugs, or high-dose systemic corticosteroids
    Inherited causes

    Order and Provider Documentation

    Documentation Required

    Identify the ordering provider and setting

    Ensure the medical record identifies the provider type or specialty and the place of service when ordering respiratory viral panel testing.

    • Include this information with the specific clinical indication and reasons for performing panel testing.
    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyPolymerase Chain Reaction Respiratory Viral Panel Testing
    Policy CodePolicy CP.MP.181
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the clinical indication, reasons for panel testing, provider specialty, and place of service in the medical record.
    SourceLink
    On This Page
    Medical Necessity CriteriaQualifying Clinical IndicationsTesting FrequencyCovered Codes and Billing CategoriesDocumentation and Denial RiskRespiratory Viral Panel TestingKey TermsOrder and Provider Documentation
    POS 19, 21, 22, or 23
  1. Severe established respiratory pathology with possible antibiotic treatment: For a panel testing six or more pathogens, the member is immunocompetent, has severe and established underlying respiratory pathology such as severe asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, or radiation therapy to the lung, and treatment with antibiotics may be indicated according to established guidelines.
  2. Large respiratory viral panel
    Pathogen limit6 pathogens or more
    Additional requirementSection I criteria must be met, plus at least one additional eligibility criterion
    CPT target ranges
    CPT 876313-5 targets
    CPT 876326-11 targets
    CPT 8763312-25 targets
  3. Targeted testing would provide sufficient information, the panel lacks the minimum pathogens needed for clinical decision making, or the test lacks equivalent or superior analytical and clinical validity to established standard-of-care methods.
  4. Documentation Required

    Additional Criteria for Panels With Six or More Pathogens

    Panels testing for six or more pathogens are medically necessary only when all criteria in section I are met and at least one additional qualifying condition applies.

    • Testing is performed in a healthcare setting caring for critically ill individuals, including an emergency department, inpatient hospital, or observation setting.
    • The member/enrollee is immunocompromised as defined in section I.A.2.
    • The member/enrollee is immunocompetent and has severe, established respiratory pathology—such as severe asthma, COPD, cystic fibrosis, pulmonary fibrosis, or radiation therapy to the lung—and antibiotic treatment may be indicated under established guidelines.
    Billing Rule

    Required Billing Context for Larger-Panel Codes

    For larger-panel codes, billing must include the required place-of-service or diagnosis-code context. Codes in Table 2 support medical necessity when billed with a Place of Service code listed in Table 3, or with a qualifying diagnosis-code combination included in both Table 4 and Table 5.

    • Applicable larger-panel codes include 0115U, 0202U, 0223U, 0225U, 87632, and 87633.
    • Qualifying Place of Service codes: 19 Off Campus-Outpatient Hospital; 21 Inpatient Hospital; 22 Outpatient Hospital (Observation); 23 Emergency Room-Hospital.
    • If a listed Place of Service code is not used, submit a diagnosis-code combination that qualifies in both Tables 4 and 5.
    Inherited diseases affecting the immune system, such as congenital immunoglobulin deficiencies
    Equivalent or superior test performance
    Analytical validityThe registered test's analytical validity must be equivalent or superior to established standard-of-care methods
    Clinical validityThe registered test's clinical validity must be equivalent or superior to established standard-of-care methods
    Reference methods and scopeComparison includes methods such as culture or pathogen-specific PCR for the majority of targets included on the panel